ZA957891B - Combination of an oploid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholosm and alcohol dependence - Google Patents

Combination of an oploid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholosm and alcohol dependence

Info

Publication number
ZA957891B
ZA957891B ZA957891A ZA957891A ZA957891B ZA 957891 B ZA957891 B ZA 957891B ZA 957891 A ZA957891 A ZA 957891A ZA 957891 A ZA957891 A ZA 957891A ZA 957891 B ZA957891 B ZA 957891B
Authority
ZA
South Africa
Prior art keywords
serotonin reuptake
reuptake inhibitor
antagonist
selective serotonin
alcoholosm
Prior art date
Application number
ZA957891A
Other languages
English (en)
Inventor
Leonard Cook
Original Assignee
Du Pont Merck Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Merck Pharma filed Critical Du Pont Merck Pharma
Publication of ZA957891B publication Critical patent/ZA957891B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA957891A 1994-09-19 1995-09-19 Combination of an oploid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholosm and alcohol dependence ZA957891B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30885994A 1994-09-19 1994-09-19

Publications (1)

Publication Number Publication Date
ZA957891B true ZA957891B (en) 1997-03-19

Family

ID=23195683

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA957891A ZA957891B (en) 1994-09-19 1995-09-19 Combination of an oploid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholosm and alcohol dependence

Country Status (11)

Country Link
US (1) US5958962A (es)
EP (1) EP0782445B1 (es)
AT (1) ATE214276T1 (es)
AU (1) AU3419995A (es)
CA (1) CA2197554A1 (es)
CO (1) CO4410317A1 (es)
DE (1) DE69525847T2 (es)
DK (1) DK0782445T3 (es)
HR (1) HRP950485A2 (es)
WO (1) WO1996009047A1 (es)
ZA (1) ZA957891B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001848A (en) * 1996-03-25 1999-12-14 The Regents Of The University Of California Bromocriptine for the treatment of alcoholics diagnosed with the D2 dopamine receptor DRD2 A1 allele
ATE256457T1 (de) * 1997-07-01 2004-01-15 Pfizer Prod Inc In gelatine eingekapselte sertarline dosierungsformen
BR9810403A (pt) 1997-07-01 2000-08-29 Pfizer Sais da sertralina e formas de dosagem de liberação sustentada da sertralina
AU1018801A (en) * 1999-10-29 2001-05-14 Novo Nordisk A/S Use of 3,4-substituted piperidines
DK2283842T3 (en) * 2000-02-08 2015-05-26 Euro Celtique Sa Oral opioid agonist formulations secured against forgery
US7034036B2 (en) * 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
EP1262196A3 (en) * 2001-05-23 2002-12-18 Pfizer Products Inc. Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
US7034059B2 (en) 2001-07-02 2006-04-25 Sepracor Inc. Methods of using norfluoxetine
HUP0401022A3 (en) * 2001-08-14 2006-11-28 Biotie Therapies Corp Method for the preparation of pharmaceutical compositions containing opioid antagonist for treating alcoholism or alcohol abuse
US20140271788A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Sublingual and buccal film compositions
CN1320886C (zh) 2002-05-17 2007-06-13 杜克大学 安非他酮与抗惊厥药在制备治疗肥胖症的药物的用途
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
DE10237057A1 (de) * 2002-08-09 2004-03-25 Grünenthal GmbH Opioid-Rezeptor-Antagonisten in Pflasterformulierungen
EP1870096A3 (en) * 2003-04-29 2011-04-20 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
DK2316456T3 (en) 2003-04-29 2017-09-11 Orexigen Therapeutics Inc Compositions for affecting weight loss comprising an opioid antagonist and bupropion
JP2007526438A (ja) * 2003-06-06 2007-09-13 コンビナトルックス インコーポレイテッド 組成物の組み合わせの多次元評価システムおよび方法
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
US20060160750A1 (en) * 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
EP1734955A2 (en) 2004-01-13 2006-12-27 Duke University Compositions of an anticonvulsant and an antipsychotic drug for affecting weigt loss
US20060100205A1 (en) * 2004-04-21 2006-05-11 Eckard Weber Compositions for affecting weight loss
EP3132792B1 (en) 2005-11-22 2019-09-11 Nalpropion Pharmaceuticals, Inc. Composition and methods for increasing insulin sensitivity
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
EP1954316A1 (en) * 2005-11-28 2008-08-13 Orexigen Therapeutics, Inc. Methods of treating anxiety disorders
US20070212307A1 (en) * 2006-02-10 2007-09-13 Daniel Wermeling Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20170077291A (ko) 2006-11-09 2017-07-05 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
KR101654176B1 (ko) 2006-11-09 2016-09-09 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
US9138430B2 (en) * 2007-12-27 2015-09-22 Mylan Specialty L.P. Formulation and method for the release of paroxetine in the large intestine
JP2011521973A (ja) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
US20100168119A1 (en) 2008-11-05 2010-07-01 Pharmorx, Inc. Compositions and methods for minimizing or reducing agonist-induced desensitization
AU2011203867B2 (en) 2010-01-11 2015-12-03 Nalpropion Pharmaceuticals Llc Methods of providing weight loss therapy in patients with major depression
ES2802048T3 (es) 2012-06-06 2021-01-15 Nalpropion Pharmaceuticals Llc Composición para uso en un método para el tratamiento de sobrepeso y obesidad en pacientes con alto riesgo cardiovascular
JP6406713B2 (ja) 2013-01-30 2018-10-17 ファーモレックス セラピューティクス， インコーポレイテッド 低用量薬剤によるうつ病および他の疾患の処置
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
EP3082816B1 (en) 2013-12-20 2019-03-20 Indivior UK Limited Intranasal naloxone compositions and methods of making and using same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777173A (en) * 1987-03-25 1988-10-11 Bristol-Myers Company Method for treatment of alcohol abuse
WO1992019241A1 (en) * 1991-05-07 1992-11-12 Dynagen, Inc. A controlled, sustained release delivery system for smoking cessation
US5366990A (en) * 1991-11-14 1994-11-22 Reid Larry D Method for treating alcohol abuse and alcoholism
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor

Also Published As

Publication number Publication date
EP0782445B1 (en) 2002-03-13
DK0782445T3 (da) 2002-05-06
ATE214276T1 (de) 2002-03-15
AU3419995A (en) 1996-04-09
CO4410317A1 (es) 1997-01-09
CA2197554A1 (en) 1996-03-28
DE69525847T2 (de) 2002-09-05
US5958962A (en) 1999-09-28
EP0782445A1 (en) 1997-07-09
WO1996009047A1 (en) 1996-03-28
HRP950485A2 (en) 1997-08-31
DE69525847D1 (de) 2002-04-18

Similar Documents

Publication Publication Date Title
ZA957891B (en) Combination of an oploid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholosm and alcohol dependence
WO2002038142A3 (en) Serotonergic compositions and methods for treatment of mild cognitive impairment
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
PT97615A (pt) Metodo para atingir um efeito terapeutico sinergistico com composicoes terapeuticas contendo pelo menos dois agentes terapeuticos seleccionados a partir de um inibidor de renina, um inibidor de enzima de conversao de angiotensina i e um antagonista de angiotensina ii
WO2000002549A8 (en) Composition for and method of treating neurological disorders
HK1032542A1 (en) Combination for the treatment of alcohol dependence containing an opioid antagonist and nmda receptor complex modulator
EP1003510A4 (en) METHOD FOR TREATING HEADACHE WITH TOPICAL ANESTHETIC COMPOSITIONS
EP1262196A3 (en) Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
CA2275167A1 (en) The topical use of kappa opioid agonists to treat ocular pain
AU5170400A (en) Topical application of muscarinic and opioid agents for treatment of tinnitus
BR9508406A (pt) Uso de um composto e método para o tratamento e/ou profilaxia em mamíferos
HK1024164A1 (en) Use of composition and a cosmetic method for reducing or preventing stinging
CA2189762A1 (en) Use of no scavengers, inhibitors or antagonists in the treatment of migraine
NO20035038D0 (no) Forhindring av avhengighet ved smertebehandling
HK1015692A1 (en) Ctla-8 in combination with g-csf or with g-csf and il-6, and use of ctla-8, for treating infections
WO1998041238A3 (en) Methods and kits for treating and diagnosing leiomyomas
ZA949564B (en) Method for treating constipation using dimeticone.
IL118491A0 (en) Use of pyrrolidine derivatives in the treatment of alcoholism
RO118794B1 (ro) Metodă de tratament a unor stări dependente de steroizii gonadici
EP1009421A4 (en) PROCESS AND COMPOSITIONS FOR IMPROVED Wounds Healing
WO1995005364A3 (en) Inhibitors of biogenic amine transporters
IL129267A0 (en) Treatment of urinary incontinence and compositions for use therein
IL124870A0 (en) Nitric oxide (no) synthase inhibitor to treat or prevent type ii diabetes
MX9701532A (es) Procedimiento para aumentar los niveles de testosterona.
ES2119581A1 (es) Utilizacion de fragmentos de timosina y/o sus derivados